Table 1

Performance of participating laboratories in the International Gonococcal Antimicrobial Susceptibility Comparison Program between 2013 and 2015

Laboratory code	Test method used	GC agar brand/supplement*	No. of panels tested	Antibiotics tested†								Per cent agreement between MICs of participant and modal MICs		Per cent concordance between interpretations of participant and modal interpretations
Laboratory code	Test method used	GC agar brand/supplement*	No. of panels tested	Pen	Spec	Tet	Ery	Cx	Cip	Ce	Azi
1	Kirby-Bauer	Oxoid/Vitox	1	X		X		X	X			72.2%	(13/18)	81.5%	(22/27)
2	E-test	Oxoid+in house/Vitox	3	X	X	X	X	X	X		X	82.0%	(109/133)	92.0%	(160/174)
3	E-test/agar dilution‡	Difco/Isovitalex	3	X	X	X		X	X	X	X	97.0%	(129/133)	99.5%	(188/189)
4	E-test	Oxoid/Vitox	1	X	X	X		X	X		X	94.1%	(16/17)	100.0%	(24/24)
5	E-test	Oxoid/Vitox	2	X		X		X	X			70.7%	(29/41)	83.6%	(61/73)
6	Agar dilution	Oxoid+Difco/Kellogg	3	X		X	X	X	X	X	X	91.7%	(110/120)	94.0%	(158/168)
7§	E-test	Oxoid/Isovitalex	2	X				X	X			82.4%	(14/17)	100.0%	(24/24)
8	Agar dilution	Difco/Britalex	1	X		X		X	X	X	X	97.5%	(79/81)	96.0%	(96/100)
9	Agar dilution	Oxoid/Vitox	1	X	X	X		X	X	X	X	79.6%	(43/54)	87.1%	(54/62)
10¶	Agar dilution	Difco/Isovitalex	1	X	X	X	X	X	X	X	X	60.0%	(9/15)	64.7%	(22/34)
12	Agar dilution	Difco/Kellogg	2	X	X	X	X	X	X	X	X	93.5%	(86/92)	93.4%	(128/137)

*Media and supplements purchased in respective countries.
†Etest Pen, penicillin; Spec, spectinomycin; Tet, tetracycline; Ery, erythromycin; Cx, ceftriaxone; Cip, ciprofloxacin; Ce, cefixime; Azi, azithromycin.
‡Etest for most of panel 1, agar dilution for panel 2 and Etest for panel 3.
§Only one control and three test isolates were available for testing.
¶Only one control and four test isolates were viable for testing.